J&J to buy pharma firm Actelion in $30 billion all-cash deal
US healthcare giant Johnson & Johnson has agreed to buy biotech firm Actelion for $30 billion (₹2 lakh crore) in its largest deal ever. The all-cash deal includes a spin out of Actelion's research and development unit into a standalone company. Notably, the deal comes amid US President Donald Trump persuading US companies to keep their operations in the country.